Journal
ANALYTICAL CHEMISTRY
Volume 89, Issue 21, Pages 11679-11684Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.analchem.7b03114
Keywords
-
Categories
Funding
- Hong Kong Baptist University [FRG2/16-17/007]
- Health and Medical Research Fund [HMRF/14130522, 14150561]
- Research Grants Council [HKBU/12301115, HKBU/201913]
- National Natural Science Foundation of China [21575121, 21628502]
- Guangdong Province Natural Science Foundation [2015A030313816]
- Hong Kong Baptist University Century Club Sponsorship Scheme
- Interdisciplinary Research Matching Scheme [RC-IRMS/15-16/03]
- Innovation and Technology Fund [ITS/260/16FX]
- Matching Proof of Concept Fund [MPCF-001-2017/18]
- Science and Technology Development Fund, Macao SAR [098/2014/A2]
- University of Macau [MYRG2015-00137-ICMS-ARCM, MYRG2016-00151-ICMS-QRCM, MRG044/LCH/2015/ICMS]
Ask authors/readers for more resources
beta-Galactosidase (beta-gal) is an important biomarker for ovarian cancers. In this work, we designed and synthesized a novel iridium(III)-based probe 1 for discriminating ovarian carcinoma cell lines from normal cell lines. The probe could detect beta-gal even in the presence of a highly autofluorescent background. The probe also showed a good linear response to beta-gal between 0 and 30 U/mL, with a detection limit of 0.51 U/mL. Importantly, complex 1 could selectively light up ovarian carcinoma cells) while exhibiting negligible luminescence in normal cells. Overall, complex 1 could be potentially used as a useful probe for detecting beta-gal expression in the context of ovarian cancer diagnostics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available